[go: up one dir, main page]

CN1086589C - 疫苗 - Google Patents

疫苗 Download PDF

Info

Publication number
CN1086589C
CN1086589C CN94194554A CN94194554A CN1086589C CN 1086589 C CN1086589 C CN 1086589C CN 94194554 A CN94194554 A CN 94194554A CN 94194554 A CN94194554 A CN 94194554A CN 1086589 C CN1086589 C CN 1086589C
Authority
CN
China
Prior art keywords
mpl
antigen
virus
vaccine
emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94194554A
Other languages
English (en)
Other versions
CN1138298A (zh
Inventor
帕特里夏·M·莫米恩
内森里·M-J·加肯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of CN1138298A publication Critical patent/CN1138298A/zh
Application granted granted Critical
Publication of CN1086589C publication Critical patent/CN1086589C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Edible Oils And Fats (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供了疫苗组合物，含有一种水包油乳液，该乳液可任选地与3-脱氧酰基化单磷酰脂A和QS21相组合。该疫苗组合物是许多免疫应答的强有力的诱导剂。

Description

疫苗
本发明涉及新的疫苗制剂，及其生产方法以及该疫苗制剂在医学上的应用。特别是，本发明涉及一种水包油乳液。这种乳液包括生育酚、角鲨烯、吐温80、Span 85(司盘85)以及卵磷脂，并且具有有效的佐剂特性。含有一种来源于Quillaja Saponaria Molina的树皮的HPLC纯化的非毒性组分，QS21，和/或3脱氧酰基化的单磷酰脂A(3De-O-acylated monophosphoryl lipid A，3D-MPL)，以及这样的水包油乳液进行组合的疫苗也是本发明的一部分。
从GB 2220211(Ribi)知道了3脱氧酰基化的单磷酰脂A。从化学上说，它是一种具有4，5或6酰基化的链的3脱氧酰基化的单磷酰脂A的混合物，由Ribi Immunochem Montana制备。在国际专利申请NO.92/116556中公开了3脱氧酰基化的单磷酰脂A的一种优选形式。
QS21是一种来自南美的Quillaja Saponana Molina树的树皮的经Hplc纯化的皂角苷(Saponin)的非毒性组分，其生产方法公开(以QA 21形式)于美国专利NO.5,057,540中。
水包油乳液本身是现有技术中已知的，并且已有人建议可将其用作为佐剂组合物(EPO 399843)。
本发明是基于下列惊人发现，与现有技术的乳液不相同的本发明的水包油乳液，含有生育酚或者含有结合了QS21和/或3D-MPL的生育酚，从而增强了对给定抗原的免疫应答。这种增强作用比迄今为止以前的所有同类制剂能提供更好的免疫应答。
另外，当将本发明的水包油乳液与3D-MPL和QS21一起配制时是IgG2a产生和TH1细胞应答的优选的刺激剂。这是有利的，因为在细胞介导的应答中已知包含有TH1应答。的确在鼠中IgG2a的诱导是与这样一种免疫应答相关的。
例如以这种方式组合的HIV抗原gp120的疫苗制剂可强有力地增效诱导对gp 120蛋白质的特异的免疫应答。
观察到可能诱导强的细胞溶解的T淋巴细胞应答的结果很有意义，因为在一些动物模型中已经证明这种细胞应答诱导了抵抗疾病的保护作用。
本发明人已经证明，佐剂QS21和3D-MPL以及在一起的水包油乳液与一种抗原结合后在脾脏中导致对CS蛋白质特异性的CTL的强力诱导作用。QS21本身也增强了CTL的诱导，而3D-MPL不能。
当胞内合成靶抗原时(例如由病毒，胞内细菌产生的感染，或在肿瘤中)容易看到CTL的诱导作用，因为由抗原的蛋白质裂解产生的肽可以进入合适的加工途径，导致以与I类分子相结合形式呈现在细胞膜上。但是，一般来说，预形成的可溶性抗原没有到达该加工和呈现途径，并且没有诱导I类范围内的CTL。因此，可诱导抗体和T辅助应答的常规的非活性疫苗一般不能诱导CTL介导的免疫应答。两种佐剂QS21和3D-MPL与水包油乳液结合在一起能够克服基于重组蛋白质的疫苗的严重的局限性，并可诱导更宽范围的免疫应答。
已经证明在鼠模型系统中特异于CS蛋白质的CTL可抵抗疟疾(Romero等人，Nature 341：323(1989))。在人试验中，当将志愿者用恶性疟原虫的被辐射过的子孢子体进行免疫接种后，可显示出抵抗随后的疟疾的进攻，显示出诱导出了特异于CS表面抗原决定簇的CTL(Malik et al.Proc.Natl.Acad.Sci.USA 88：3300(1991))。
可诱导出对以重组分子形式给药的一种抗原具特异性的CTL的能力是与疟疾疫苗的研制相关的，因为基于免疫应答的产生及其特性，使用经辐射的子孢子体是不切实际的。
RTS是一种杂合蛋白质，它基本上含有借助于乙肝表面抗原的pre S2部分的四个氨基酸连接到乙肝病毒的表面(S)抗原上的恶性疟原虫的环子孢子体(CS)蛋白质的整个C末端部分。其完整结构公开于共同待批国际专利申请NO.PCT/EP 92/02591，该申请要求了UK专利申请NO.9124390.7的优先权，其公开号为WO 93/10152。当在酵母中表达时产生出脂蛋白颗粒形式的RTS，并且当以与HBV的S抗原共表达时产生出已知为RTS，S的混合颗粒。
除了人免疫缺陷病毒和疟疾疫苗外，诱导CTL应答的能力有利于抗单纯性疱疹病毒，巨细胞病毒以及通常的具有胞内生活期的病原体的所有病例的疫苗。
同样，将重组肿瘤抗原和两种佐剂组合后可诱导特异于已知肿肿瘤抗原的CTL。这为研制抗癌疫苗提供了条件。
在一些系统中，将3D-MPL和QS21以及水包油乳液结合起来能够协同地增强干扰素γ的产生。本发明人利用已知的名为gD2t的单纯性疱疹抗原证明了3D-MPL和QS21与水包油乳液组合在一起的潜力。gD2t是一种从HSV-2上切下的可溶性糖蛋白D，并且是采用Berman等人的方法(Science 222 524-527)在CHO细胞中产生的。
IFN-γ的分泌是与抗胞内病原体，包括寄生虫，细菌和病原体的保护性应答相关的。由IFN-γ对巨噬细胞的激活增强了胞内对微生物的杀伤力以及增强Fc受体的表达。也可能存在直接的细胞毒性，尤其是在与淋巴毒素(TH1细胞的另一种产物)进行增效作用时。IFN-γ既是NK细胞的诱导剂又是其产物，NK细胞是保护作用的主要的固有的效应子。通过IFN-γ或者其他机制进行的TH1型应答为IgG2a免疫球蛋白同型提供了优先帮助。
糖蛋白D定位于病毒包膜上，并且也存在于受感染细胞的胞质中(Eisenberg R.J.等人J.of Virol.1980 35：428-435)。它含有包括信号肽在内的393个氨基酸并且具有约60KD的分子量。在所有的HSV包膜糖蛋白中，它可能是得到最详细表征的一种(Cohen等人，J.Virology 60：157-166)。已知在体内它对于病毒粘附到细胞膜上起着关键的作用。而且，已证明糖蛋白能够在体内诱导出中和抗体(Eing等人，J.Med.Virology 127：59-65)。但是，尽管在患者血清中存在高效价的中和抗体，潜伏的HSV2病毒仍能被重新激活并诱导疾病复发。因此，显然仅具有诱导中和抗体的能力不足于控制疾病。
为了防止疾病复发，任何疫苗需要不仅刺激中和抗体，而且激发由T细胞，特别是毒性T细胞介导的细胞免疫作用。
对于gD2t例子，它是308个氨基酸的HSV2糖蛋白D，它含有天然存在的糖蛋白的第1-306个氨基酸，在该被截短的蛋白质的C-末端添加了天冬酰胺和容氨酰胺。这种蛋白质形式包括信号肽，将该信号肽裂解后产生成熟的283氨基酸蛋白质。在Genentech的欧洲专利EP-B-139 417中已描述了在中国仓鼠卵细胞中生产这样一种蛋白质。
该成熟的被截短的糖蛋白D(rgD2t)或从哺乳动物细胞中分泌的等同蛋白质优先用于本发明的疫苗制剂中。
在患有生殖器疱疹的豚鼠模型中本发明的制剂可十分有效地诱导保护性免疫作用。甚至在具有非常低剂量抗原(例如低至5μgrgD2t)时该制剂可保护豚鼠抵抗初次感染，并且也激发了特异性的中和抗体应答。本发明人利用本发明的制剂也证实了在鼠中效应细胞介导的TH1型应答。
因此，在一个优选实施方案中，本发明提供了一种含有与3-脱氧酰基化的单磷酰脂A，QS21和一种水包油乳液相组合的抗原的疫苗或药物制剂，该水包油乳液含有一种可代谢的油，例如角鲨烯，α-生育酚和吐温80。这样一种制剂适合于很多的单价或多价疫苗。另外，该水包油乳液可含有span 85。3-脱氧酰基化的单磷酰脂A的一种优选形式公开于公开号为NO.92116556的Smithkline BeechamBiologicals s.a.的国际专利申请中。
该水包油乳液可以单独使用或与其他佐剂或免疫刺激剂结合起来使用，因此本发明的一个重要实施方案是一种含有角鲨烯或另一种可代谢油，α-生育酚和吐温80的水包油制剂。该水包油乳液还可含有span 85和/或卵磷脂。
优选的疫苗制剂含有能够引发抗人或动物病原体的免疫应答的抗原或抗原组合物，所述抗原或抗原组合物来源于HIV-1(例如gp120或gp160)，任何猫的免疫缺陷病毒，人或动物疱疹病毒，例如gD或其衍生物或立即早期蛋白如来源于HSV1或HSV2的ICP27，巨细胞病毒((尤其是人)(例如gB或其衍生物)，水痘带状疱疹病毒(例如gpI，II或III)，或者来源于例如已肝病毒的肝炎病毒，例如乙肝表面抗原或其衍生物，甲肝病毒，丙肝病毒和戊型肝炎病毒，或者来自于其他病毒病原体，例如呼吸道合胞体病毒，人乳头瘤病毒或流感病毒、或者来源于细菌病原体如沙门氏菌、奈瑟氏菌、螺旋体(例如OspA或OspB或其衍生物)，或者衣原体，或博德特氏菌例如P.69，PT和FHA，或来源于寄生虫如疟原虫或者弓形体。
该制剂还可含有一种抗肿瘤抗原并适用于采用免疫治疗法治疗癌症。
在一种适于免疫治疗的患有B细胞淋巴瘤的动物模型中，当在第0天时将BCL-1鼠淋巴瘤细胞静脉注射到Balb/c小鼠中，并在第3天，10天和20天用BCL-1同种异型给小鼠免疫接种，就抗体效价和存活率(该组为存活率为100％的唯一组)而言，SB62/MPL/QS21制剂被证明为最有效力。同样，该制激发针对所包含的抗原的细胞毒性T淋巴细胞的能力，使其成为作为癌抗原制剂的良好的候选物(例如用于通过活性免疫接种而对肿瘤进行免疫治疗的黑色素瘤抗原MAGE-1和MAGE-3)。
该制剂还适用于与疱疹的轻颗粒一起使用，例如描述于国际专利申请NO.PCT/GB 92/00824，以及国际专利申请NO.PCT/GB 92/00179的制剂。
乙肝表面抗原的衍生物是本领域内熟知的，并且特别包括那些在欧洲专利申请EP-A-414374；EP-A-0304578，和EP 198-474中描述的PreS1，PreS2 S抗原。在一个优选的方面，本发明的疫苗制剂包括HIV-1抗原，gp120，尤其是当在CHO细胞中表达时，在另一实施方案中，本发明的疫苗制剂包括如上文中定义的gD2t。
在本发明的又一方面，提供了如本发描述的在医学上使用的疫苗。
QS21与3D-MPL的比例通常是在1∶10至10∶1的范围，优选的是1∶5-5∶1并且实质上经常是1∶1。达到最适增效作用的优选范围是2.5∶1到1∶1的3D MPL∶QS21。当给人使用时通常疫苗中存在的QS21与3D MPL的比例为1μg-100μg/每剂量的范围，优选的是10μg-50μg/每剂量。水包油乳液通常含有2-10％的角鲨烯，2-10％α-生育酚以及0.3-3％吐温80。优选的是角鲨烯与α-生育酚的比例是等于或者低于1，因为这样使乳液更稳定。还可以存在1％含量的Span 85。在某些情况下，本发明的疫苗进一步含有一种稳定剂是有利的。
通常疫苗的制备可参见New Trends and Developments in Va-ccines，edited by Voller et al.，University Park Press，Baltimore，Maryland，U.S.A.1978。脂质体内进行包埋的方法例如可参见Fullerton，美国专利4,235,877的描述。蛋白质与大分子的结合例如公开于由Likhite的美国专利4,372,945以及Armor等人的美国专利4,474,757。
所选择单疫苗剂量中蛋白质的量为在典型的接种人中诱导产生免疫保护应答而无显著的毒副作用所需的量。该量将随所使用的特定免疫原以及如何提供而变化。通常，单个剂量含有1-1000μg的蛋白质，优选的是1-100μg，更优选的为4-40μg。采用包括观察个体中合适免疫应答的标准研究确定用于特定疫苗中的最适量。在首次免疫接种之后，受试个体可接受一次或者适当间隔的几次加强免疫接种。
本发明的药剂可用于预防和治疗目的。
因此，一方面，本发明提供了一种治疗方法，该方法包括给患者施用有效量的本发明的疫苗。
下面实施例阐明本发明。
                      实施例1
含有HIV-1的gp 120抗原的疫苗制剂
制备两种佐剂制剂，每种含有下列水包油乳剂成分。
SB 26：5％角鲨烯，5％生育酚，0.4％吐温80；颗粒大小是500nm。
SB 62：5％角鲨烯，5％生育酚，2.0％吐温80；颗粒大小是180nm。
1(a)乳剂SB 62的制备(2倍浓缩)
将吐温80溶于磷酸缓冲盐水(PBS)中得到溶于PBS中的2％的溶液。为了提供100ml两倍浓缩乳液，将5克DLα生育酚和5ml角鲨烯涡流以便彻底混合。加入90ml PBS/吐温溶液并彻底混合。然后将得到的乳液通过一个注射器并且最后利用MllOS微射流机器进行微射流。得到的油滴具有约180nm的大小。
1(b)乳液SB26的制备
以类似的方式利用0.4％吐温80制备该乳液。
1(c)以类似的方式制备表1中描述的其他乳液。下列实施例中详细描述了检测这些乳液的试验。
1(d)gp120 QS21/3D MPL水包油制剂的制备
向1a)或b)或c)乳液中加入某体积的两倍浓缩的rgp 120(20μg或100μg)并且混合。将它与50μg/ml的3D-MPL和20μg/ml的QS21合并，得到最后的制剂。按照盐含量和pH值调整缓冲液。
表3显示利用来自HIV的gp120和50μg/ml 3D-MPL(MPL)以及20μg/ml的QS21的SB26的效果。结果显示在第二次(PII)和第三次(PIII)接种后效价的几何平均值(GMT)，以及对淋巴细胞增殖和γ干扰素产生作出的细胞介导的应答(CMI)。
                     实施例2
引言：一种HIV gp120乳液系统的评估
在该实验中，对四个乳液[SB26，SB62，SB40，SB61]进行比较。对各个制剂成分(抗原，乳液，3D-MPL，QS21)的效应进行评估。
2(b)所使用的动物试验组
使用22组，每组5个动物，使每组接受不同的疫苗制剂。
-1-4组：gp120(10μg)/无乳液±[3D-MPL，QS21]
-5-9组：gp120(10μg)/SB26±[3D-MPL，QS21]
-10组：无抗原/SB26+[3D-MPL，QS21]
-11-12组：gp120(10μg)/SB62±[3D-MPL，QS21]
-13-16组：gp120(10μg)/SB40±[3D-MPL，QS21]
-17-20组：gp120(10μg)/SB61±[3D-MPL，QS21]
-21-22组：gp120(5μg)/SB26±[3D-MPL，QS21]
-分析：抗gp120W61D的抗体效价以及同型分析(所有组)
2(c)免疫接种以及抽血时间表
-用gp120W61D对动物进行免疫接种，所述gp120W61D是配制于每剂量存在5μg 3D-MPL和5μg QS21的不同的油水乳液中。阴性对照接受没有抗原的等同制剂。
-在0和14天时皮下注射免疫接种动物。所给药的每次注射剂量为100μl。
-在免疫接种前(0天)以及在免疫接种之后第14天(第一次接种后)，第21以及28(第二次接种后第7和第14天)天获取血样品。
2(d)血清学应答分析：
-第一次接种后和第二次接种后的14天的血清学应答是采用针对gp120W61D的直接ELISA检测法进行评估的。
-用免疫接种之后小鼠中诱导出的gp120W61D特异性抗体的同型也对第二次接种后14天的应答进行表征。
3.结果和讨论
结果描绘于表2中。
a)在存在或不存在3D-MPL/QS21的乳液的比较：
-将SB26，SB40或SB62乳液加入到抗原中诱导出更高的抗体效价。在没有免疫刺激剂情况下，gp120特异性抗体基本上是IgG1。
-加入免疫刺激剂3D-MPL和QS21诱导了巨大的血清学应答并且抗体从IgG1型转变为IgG2a/IgG2b：这与细胞介导的免疫相关。
优选的组合是[SB26+MPL+QS21]。
c)gp120/SB26制剂：
在8组和9组之间没有观察到血清学应答之间的显著差异：在本制剂其他成分之前或之后加入gp120。
d)抗原剂量：
配制于SB26中的5和10μg gp120诱导了高血清应答(5-8组以及21-22组)。
                         实施例3
HSV rgD2t制剂
按照实施例1(a)中提出的类似方式，制备含有单纯疱疹抗原rgD2t的制剂并用于免疫接种豚鼠。所述制剂诱导出抵抗豚鼠模型中复发和起始疾病的保护作用。
                        实施例4
利用个体基因型作为免疫原筛查用于诱导保护性抗淋巴瘤应答的佐剂。
利用来自BCL1淋巴瘤细胞的个体基因型给Balb/c小鼠进行治疗性免疫接种。
由Yefenoh等人对BALB/C B细胞淋巴瘤模型进行了综述。Curr-ent opinions Immunobiology 1993 5：740-744。
用104肿瘤细胞在0天时注射(ip)的10只小鼠的组，并用溶于不同佐剂制剂中的100μg的KLH偶合的抗BCL1抗原决定簇的免疫球蛋白(KLH/Ig：1/1的比例)在第3天，10天，20天免疫接种(在背部皮下注射)。对抗KLH和抗个体基因型的血清抗体水平以及鼠死亡率进行了监测。
所检测的制剂：
组号     佐剂                        MPL：10μg
1        无(无抗原)                  QS21：10μg
2        无
3        弗氏佐剂
4        明矾
5        明矾/MPL
6        明矾/MPL/QS21
7        QS21
8        MPL/QS21
9       SB62MPL
10      SB62/MPL/QS21
12-15组：没有抗原的不同佐剂
与其他组相比，制剂8、9、10的行为均较好。在抗体效价以及存活率两方面，制剂10表现为最有效力(生存率为100％的唯一组)。
                       实施例5
RTS，S的不同制剂
a)在猴中的评价
在国际专利申请No.WO 93/10152中描述了RTS，S并且制成制剂用于给Rheusus免疫接种。每组有5个动物：
I组      RTS，S，3D-MPL(50μ)，Al(OH)3
II组     RTS，S，QS21(20μ)，Al(OH)3
III组    RTS，S，3D-MPL(50μ)，QS21(20μ)
IV组     RTS，S，3D-MPL(50μ)，QS21 Al(OH)3
V组      RTS，S，3D-MPL(10μ)，QS21 Al(OH)3
VI组     RTS，S，3D-MPL(50μ)，QS21 SB60
给动物接种并且在第一次免疫接种之后14天以及第二次免疫接种之后12天取血，并检测其抗乙肝表面免疫球蛋白。如在图1中可看到的，接受SB60中的RTS，S的动物具有的抗体效价几乎比任何其他组高出6倍。
b)用小鼠对RTS，S的各种制剂进行评估
7组动物接受下列制剂
1组      RTS，S SB26
2组      RTS，S QS21 3D-MPL
3组      RTS，S QS21 3D-MPL SB62
4组      RTS，S 3D-MPL Al(OH)3
5组      RTS，S Al(OH)3
6组      空白
7组      阴性对照
(RTS，S-5μg/剂量，3D-MPL 5μg/剂量，QS21 5μg/剂量)
给动物接种并且在第一次接种后15天以及在第二次接种之后7天和15天取血，并检测抗HBSAg抗体亚型。如在图2中可看到的，用QS21和3D-MPL配制的乳液SB62优先地和以协同增效方式加强IgG2a抗体应答，而单独的SB62或3D-MPL/QS21诱导极少的IgG2a应答。
实施例6：对不同的B burgdorferi OspA制剂的评估
6.1不同的B burgdorferi ZS7 OspA脂蛋白制剂的评估
在欧洲专利申请0418 827(Max Plank et al)中描述了B bur-gdorferi的OspA脂蛋白。
在balb/c鼠中检测下列制剂
1. OspA+Al(OH)3
2. OspA+Al(OH)3+3D-MPL(10μ)
3. OspA+Al(OH)3+3D-MPL(30μ)
4. OspA+Al(OH)3+3D-MPL(10μ)+QS21(5μ)
5. OspA+Al(OH)3+3D-MPL(30μ)+QS21(15μ)
6. OspA+SB60+3D-MPL(10μ)+QS21(5μ)
7. OspA+SB60+3D-MPL(30μ)+QS21(15μ)并且在第一次接种之后7天以及在第二次接种之后7天(在0天和14天接种)研究抗体效价和亚型。
在图3和图4中以图形式描述结果，并且证明本发明的制剂诱导出高水平的抗体并且它们优先的是IgG2a亚型。
                       实施例7
a)HSV-2 ICP27
在0天和14天时在后脚爪用各种NS1-ICP27制剂给雌性Balb/c小鼠免疫接种。每次注射含有5μg的NS1-ICP27以及SB26水包油乳液，QS21(10μg)和MPL(25μg)的组合物。在28天时取出腘淋巴结细胞并在体外用转染了ICP27基因的同系P815细胞进行刺激。用转染了ICP27和P815 ICP27阴性对照的P815靶细胞检测该培养物的特定的细胞溶解活性。
对于不同的免疫接种组以不同的效应子∶靶(E∶T)比例的具体裂解结果如下所示：ICP 27(5μg)E∶T    P815  转染了ICP27克隆121的P815100∶1  -1    030∶1   -2    -310∶1   3     03∶1    1     01∶1    2     20.3∶1  2     2ICP 27(5μg)+MPL(25μg)E∶T    P815  转染了ICP27克隆121的P815100∶1  5      730∶1   2      210∶1   1      23∶1    -1     -11∶1    -2     -20.3∶1  -4     -1ICP 27(5μg)+QS21(10μg)E∶T     P815  转染了ICP27克隆121的P815100∶1   4     1730∶1    5     1010∶1    3     73∶1     4     51∶1     3     50.3∶1   0     1ICP 27(5μg)+SB26E∶T     P815  转染了ICP27克隆121的P815100∶1   5     2030∶1    1     1910∶1    2     123∶1     -2    71∶1     1     50.3∶1   1     2ICP 27(5μg)+MPL(25μg)+QS21(10μg)E∶T     P815  转染了ICP27克隆121的P815100∶1   4     1330∶1    5     1210∶1    4     173∶1     1     31∶1     0     30.3∶1   -1    -2ICP 27(5μg)+MPL(25μg)+QS21(10μg)+SB26E∶T     P815  转染了ICP27克隆121的P815100∶1   2     2030∶1    0     1710∶1    3     193∶1     3     81∶1     1     60.3∶1   2     3在免疫接种组中获得的低ICP27特异性裂解％ICP27(5μg)+QS21(10μg)ICP27(5μg)+SB26ICP27(5μg)+MPL(25μg)+QS21(10μg)ICP27(5μg)+MPL(25μg)+QS21(10μg)+SB26而ICP27(5μg)ICP27(5μg)+MPL(25μg)是阴性
因此这些数据显示由重组NS1-ICP27在单独的水包油乳液或与QS21和MPL一起；或与QS21一起诱导出CTL。
b)用不同疫苗(NS1-ICP27/NS1-ICP27 MPL+QS21/NS1-ICP27 SB26＝MPL和QS21/仅佐剂)在脚爪处给5个Balb/c小鼠为一组的各组免疫接种。一个剂量含有10μg NS1-ICP27，10μg MPL和10μg QS21。在0天和7天进行两次免疫接种。在14天用5.2×103TCID50的HSV2菌株MS攻击小鼠。一直到攻击后14天都记录是否出现带状疱疹样的损伤和死亡。
在大肠杆菌中表达出了与流感病毒NS1片段的融合蛋白形式的HSV2的ICP27。在鼠带状疱疹样模型中对该纯化重组蛋白与MPLQS21制剂的组合物的保护效率进行评估。在用与MPL+QS21或与水包油乳液(SB26)+MPL和QS21组合的NS1-ICP27进行两次免疫接种的Balb/c小鼠可完全抵抗疾病(无带状疱疹样损伤)以及在HSV2野生型攻击之后没有死亡发出。相反，在单独用NS1-ICP27或用NS1-ICP27与SB26但没有MPL和QS21进行相组合的疫苗对小鼠进行免疫接种后没有观察到保护作用。
                                           表1
                                     两倍浓缩的载体
乳液SB 生育酚％ 角鲨烯％ 吐温80％    Span 85％    卵磷脂％         大小
    2626.163646162     555555     555555     0.40.40.60.812      000000      00.10000      500nm 90-100％800nm 10-0％500nm500nm500nm250-300nm180nm
    4040.1606566     55555     55555     0.40.410.40.4      1111.52      00.1000      500nm 80-100％800nm 20-0％500nm300nm500nm500nm
                                                   表2
                                  HIV gp 120W61D/     鼠免疫原性(94243)/BALB/C(F.P.)
   组号          免疫原(剂量)/制剂     ELISA效价(第二次接种后7天)     ％IgG1     ％IgG2a   ％IgG2b
    123456789111213141516171819202122          gP120 10μggP120 10μg+3D-MPL 5μggP120 10μg+QS21 5μggP120 10μg+3D-MPL+QS21gP120 10μg/SB26gP120 10μg/SB26+3D-MPLgP120 10μg/SB26+QS21gP120 10μg/SB26+3D-MPL+QS21SB26+3D-MPL+QS21/gP120 10μggP120 10μg/SB62gP120 10μg/SB62+3D-MPL+QS21gP120 10μg/SB40gP120 10μg/SB40+3D-MPLgP120 10μg/SB40+QS21gP120 10μg/SB40+3D-MPL+QS21gP120 10μg/SB61gP120 10μg/SB61+3D-MPLgP120 10μg/SB61+QS21gP120 10μg/SB61+3D-MPL+QS21gP120 5μg/SB26gP120 5μg/SB26+3D-MPL+QS21     4944164215155274912205873885102017816918570410348217393632028521948953209217＜5077515407375967325089242736     1005489229431732322925490317814-3174299918       0154602421557608377441567-501357061     03281842713211909425718-191314121
由LINEST计算出的gp120W61D的ELISA效价：5个单体效价的几何平均值
                                                        表3
                                           基于3D-MPL的制剂；HIV工程猴研究
           读数     GMT ELisa W61 D        GMT Neut.MN 体内DTH 体外CMI
           制剂   P11   P111     P11   P111     LP   IL-2     γIFN
    gp120(100μg)/油/水+MPL+QS21gp120(20μg)/油/水+MPL+QS21豚鼠中“过去的”gp120(100μg)/油/水+MPL   6052352026   934105015020064     1∶5001∶500   ＞1∶32001∶2400     ++   没有检测没有检测       ++

Claims (10)

1、一种疫苗组合物，包含有一种抗原和/或抗原组合物，QS21，3脱氧酰基化单磷酰脂A(3D-MPL)和水包油乳液，其中该水包油乳液具有下列组分：一种可代谢油，例如角鲨烯，α-生育酚和吐温80。
2、按照权利要求1中所述疫苗，其中QS21∶3D-MPL的比例是从1∶10到10∶1。
3、按照权利要求1或2所述疫苗组合物，能够在哺乳动物中激发针对该抗原或抗原组合物的细胞溶解性T细胞应答。
4、按照权利要求1-3任一项所述的疫苗组合物，它能够刺激干扰素γ的产生。
5、按照权利要求1-4任一项所述疫苗组合物，其中QS21∶3D-MPL的比例是从1∶1到1∶2.5。
6、如本文所述的一种疫苗组合物，其中包括来源于人免疫缺陷病毒、猫免疫缺陷病毒、单纯性疱疹病毒1型、单纯性疱疹病毒2型、人巨细胞病毒、甲、乙、丙或戊型肝炎病毒、呼吸道合胞体病毒、人乳头瘤病毒、流感病毒、沙门氏菌、萘瑟氏菌、螺旋体、衣原体、博德持氏菌、疟原虫或弓形体中的任何抗原或抗原组合物。
7、根据权利要求1-5任一项所述的疫苗，其中该抗原是肿瘤抗原。
8、权利要求1-5任一项所述组合物的应用，用于制造病毒，细菌或寄生虫感染的预防治疗的疫苗。
9、权利要求1-5任一项所述组合物的应用，用于制造病毒，细菌或寄生虫感染或癌症的免疫治疗的疫苗。
10、一种制备权利要求1-5所述疫苗组合物的方法，包括将QS21，3D-MPL和如权利要求1中定义的水包油乳液与一种抗原或抗原组合物进行混合。
CN94194554A 1993-12-23 1994-12-20 疫苗 Expired - Fee Related CN1086589C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9326253.3 1993-12-23
GB939326253A GB9326253D0 (en) 1993-12-23 1993-12-23 Vaccines

Publications (2)

Publication Number Publication Date
CN1138298A CN1138298A (zh) 1996-12-18
CN1086589C true CN1086589C (zh) 2002-06-26

Family

ID=10747069

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94194554A Expired - Fee Related CN1086589C (zh) 1993-12-23 1994-12-20 疫苗

Country Status (23)

Country Link
US (5) US6146632A (zh)
EP (4) EP0735898B1 (zh)
JP (3) JP4125781B2 (zh)
KR (1) KR100350965B1 (zh)
CN (1) CN1086589C (zh)
AT (3) ATE265228T1 (zh)
AU (3) AU1316495A (zh)
CA (1) CA2179779C (zh)
CY (2) CY2530B1 (zh)
DE (5) DE122008000054I1 (zh)
DK (3) DK0735898T3 (zh)
ES (3) ES2285036T3 (zh)
GB (1) GB9326253D0 (zh)
GR (1) GR3029750T3 (zh)
HK (3) HK1012243A1 (zh)
LU (2) LU91485I2 (zh)
NL (2) NL300363I1 (zh)
NZ (2) NZ329661A (zh)
PT (2) PT868918E (zh)
SG (2) SG49257A1 (zh)
SI (3) SI0868918T1 (zh)
WO (2) WO1995017209A1 (zh)
ZA (1) ZA9410176B (zh)

Families Citing this family (588)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) * 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ES2327693T3 (es) * 1997-08-29 2009-11-02 Antigenics Inc. Composiciones que comprenden el adyvante qs-21 y polisorbato o ciclodextrina excipiente.
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
DK1659178T3 (da) 1998-02-05 2010-07-12 Glaxosmithkline Biolog Sa Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein
PL343429A1 (en) * 1998-03-09 2001-08-13 Smithkline Beecham Biolog Combined vaccine compositions
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
GB9806095D0 (en) * 1998-03-20 1998-05-20 Smithkline Beecham Biolog Novel compounds
EP1068329A2 (en) 1998-04-07 2001-01-17 Corixa Corporation FUSION PROTEINS OF $i(MYCOBACTERIUM TUBERCULOSIS) ANTIGENS AND THEIR USES
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
CN101219217A (zh) * 1998-05-07 2008-07-16 科里克萨有限公司 佐剂组合物及其使用方法
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
AU5467899A (en) 1998-08-07 2000-02-28 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
ATE527360T1 (de) 1998-12-08 2011-10-15 Glaxosmithkline Biolog Sa Neue verbindungen abgeleitet von neisseria meningitidis
HUP0400719A3 (en) 1998-12-08 2010-08-30 Corixa Corp Compounds and methods for treatment and diagnosis of chlamydial infection
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
ATE471328T1 (de) * 1999-02-01 2010-07-15 Eisai R&D Man Co Ltd Verbindungen mit immunologischem adjuvanseffekt
GB2348132B (en) * 1999-03-02 2004-08-04 Nedaa Abdul-Ghani Nasif Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils
EP1165778B1 (en) 1999-03-11 2006-10-18 GlaxoSmithKline Biologicals S.A. Uses of casb618 polynucleotides and polypeptides
US7666988B1 (en) 1999-03-12 2010-02-23 Glaxosmithkline Biologicals S.A. BASB082 Polypeptides
CZ303653B6 (cs) * 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Imunogenní prostredek
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
HUP0202930A2 (en) * 1999-03-26 2002-12-28 Smithkline Beecham Biolog Novel compounds
EP1169347B1 (en) 1999-04-02 2008-07-02 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
JP2002542203A (ja) * 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
WO2000069456A2 (en) * 1999-05-13 2000-11-23 American Cyanamid Company Adjuvant combination formulations
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
EP1964573B1 (en) 1999-10-22 2014-11-26 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
BR0108654A (pt) 2000-02-23 2003-04-29 Smithkline Beecham Biolog Composição imunogênica, polipeptìdeo isolado, vetor de expressão ou um microorganismo vivo recombinante, célula hospedeira, processos para produzir uma composição imunogênica e um polipeptìdeo ou um fragmento imunogênico do mesmo, uso de um polipeptìdeo ou de um polinucleotìdeo que codifica um polipeptìdeo, método para o tratamento de um indivìduo pela imunoprofilaxia ou terapia, anticorpo, agonista ou antagonista ao polipeptìdeo, composto, e, processos para diagnosticar, uma doença ou uma suscetibilidade a uma doença e a presença de câncer colorretal ou uma suscetibilidade ao câncer colorretal, em um indivìduo
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001078777A2 (en) * 2000-04-13 2001-10-25 Mossman, Sally Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
AU5810201A (en) 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
AU2001268472A1 (en) * 2000-06-16 2002-01-02 Smith Kline Beecham Corporation Icp27-binding polynucleotides
WO2001098460A2 (en) 2000-06-20 2001-12-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AR029540A1 (es) 2000-06-28 2003-07-02 Corixa Corp COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
PT1946769E (pt) 2000-06-29 2012-06-27 Smithkline Beecham Biolog Composição de vacina multivalente com dose reduzida de haemophilus influenzae de tipo b
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
EP1307466B1 (en) 2000-07-31 2005-11-16 Eisai Co., Ltd. Immunological adjuvant compounds
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
KR100831139B1 (ko) * 2000-10-18 2008-05-20 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
EP1671981A3 (en) 2000-10-27 2006-07-05 Chiron SRL. Nucleic acids and proteins from streptococcus group A
EP1370283A4 (en) * 2000-11-16 2004-12-15 Univ Maryland PREVENTION OF RECURRENT VIRAL DISEASES
AU2002220018A1 (en) 2000-11-29 2002-06-11 Colorado State University System for in-vitro fertilization with spermatozoa separated into x-chromosome and y-chromosome bearing populations
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
EP2339035A1 (en) 2000-12-07 2011-06-29 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
EP1423421A2 (en) * 2001-01-26 2004-06-02 Walter Reed Army Institute of Research Isolation and purification of p. falciparum merozoite protein-1 42 vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP2241309A3 (en) 2001-07-10 2012-12-26 Corixa Corporation Methods for encapsulation of proteins and adjuants in microspheres
CN1561230B (zh) * 2001-07-26 2011-09-07 奥塔戈创新公司 抗原组合物
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CA2476755C (en) 2001-12-17 2014-08-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US7030094B2 (en) * 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
MXPA04010255A (es) 2002-04-19 2008-03-04 Univ Toronto Metodos inmunologicos y composiciones para el tratamiento de la enfermedad de alzheimier.
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
EP1532161B1 (en) 2002-06-13 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Vectors for expression of hml-2 polypeptides
DE60335755D1 (de) 2002-07-18 2011-02-24 Univ Washington Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
US20050250175A1 (en) * 2002-08-02 2005-11-10 Takehiko Nomura Bacterial cell wall skeleton component preparaion
PL220107B1 (pl) 2002-08-02 2015-08-31 Glaxosmithkline Biolog Sa Preparat immunogenny, szczepionka oraz zastosowanie tej szczepionki
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7169548B2 (en) 2002-09-13 2007-01-30 Xy, Inc. Sperm cell processing and preservation systems
ES2608048T3 (es) 2002-10-11 2017-04-05 Glaxosmithkline Biologicals Sa Vacunas polipeptídicas para protección amplia contra linajes meningocócicos hipervirulentos
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
DE60332477D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
ES2309485T3 (es) 2003-01-06 2008-12-16 Wyeth Composiciones y procedimientos para diagnosticar y tratar los canceres de colon.
CN102319427A (zh) 2003-01-30 2012-01-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
CA2952056C (en) 2003-03-28 2020-04-28 Inguran, Llc Apparatus, methods and processes for sorting particles and for providing sex-sorted animal sperm
RU2005130646A (ru) 2003-04-04 2006-01-27 Пфайзер Продактс Инк. (Us) Микрофлюидизированные эмульсии масло в воде и композиции вакцины
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7731967B2 (en) * 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
PT1631264E (pt) 2003-06-02 2009-11-03 Novartis Vaccines & Diagnostic Composições imunogénicas à base de micropartículas biodegradáveis que compreendem um toxóide de difteria e do tétano
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
ES2346314T3 (es) 2003-10-02 2010-10-14 Glaxosmithkline Biolog Sa Antigenos de b. pertussis y uso de los mismos en vacunacion.
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CA2555274A1 (en) 2004-02-05 2005-08-25 The Ohio State University Research Foundation Chimeric vegf peptides
EP1722815A1 (en) 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
US20080032384A1 (en) * 2004-04-22 2008-02-07 Takehiko Nomura Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
BRPI0510315A (pt) 2004-04-30 2007-10-16 Chiron Srl integração de vacinação com conjugado meningocócico
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP2811027A1 (en) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
WO2006031264A2 (en) 2004-05-25 2006-03-23 Oregon Health And Science University Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
AU2005249212B2 (en) * 2004-05-28 2010-05-20 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US8085126B2 (en) * 2004-07-27 2011-12-27 Honeywell International Inc. Identification with RFID asset locator for entry authorization
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006032475A2 (en) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Staphylococcal immunogenic compositions
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
PT2682126T (pt) 2005-01-27 2017-02-28 Children`S Hospital & Res Center At Oakland Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
US20090081253A1 (en) * 2005-03-23 2009-03-26 Glaxosmithkline Biologicals S.A. Composition
GB0506001D0 (en) * 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Novel use
CN103372206A (zh) 2005-03-31 2013-10-30 葛兰素史密丝克莱恩生物有限公司 针对衣原体感染的疫苗
CN101355928B (zh) 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
EP2426141B1 (en) 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Method for preventing or treating M tuberculosis infection
AU2006261342B2 (en) 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP1910410B1 (en) 2005-07-01 2011-10-26 Forsyth Dental Infirmary for Children Tuberculosis antigen detection assays and vaccines
US7618770B2 (en) 2005-07-29 2009-11-17 Xy, Inc. Methods and apparatus for reducing protein content in sperm cell extenders
EP1931417A2 (en) * 2005-09-30 2008-06-18 Transcutaneous Technologies Inc. Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles
KR20080066712A (ko) * 2005-09-30 2008-07-16 티티아이 엘뷰 가부시키가이샤 관능화된 미세바늘 경피 약물 전달 시스템, 장치 및 방법
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
EP1928539A1 (en) * 2005-09-30 2008-06-11 Tti Ellebeau, Inc. Functionalized microneedles transdermal drug delivery systems, devices, and methods
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628206A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
DE06808434T1 (de) * 2005-11-04 2009-12-17 Novartis Vaccines And Diagnostics S.R.L. Emulsionen mit freiem wässrigen phasen tensid als adjuvans für spalt-grippeimpfstoffe
US10842867B2 (en) 2005-11-04 2020-11-24 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
JP5492418B2 (ja) * 2005-11-18 2014-05-14 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法
US8900180B2 (en) * 2005-11-18 2014-12-02 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
TR201900418T4 (tr) 2005-12-22 2019-02-21 Glaxosmithkline Biologicals Sa Pnömokok polisakkarit konjugat aşısı.
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US20080033398A1 (en) * 2005-12-29 2008-02-07 Transcutaneous Technologies Inc. Device and method for enhancing immune response by electrical stimulation
CN101374859B (zh) 2006-01-17 2014-11-26 阿恩·福斯格伦 新的表面外露流感嗜血菌蛋白质(蛋白质E；pE)
KR20080089663A (ko) 2006-01-27 2008-10-07 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
BRPI0710023A2 (pt) 2006-03-30 2011-08-02 Embrex Inc métodos e composições para a vacinação de aves domésticas
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2258874B1 (en) 2006-06-02 2015-03-18 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy
WO2009030978A2 (en) 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
JP5275982B2 (ja) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US8128921B2 (en) * 2006-07-11 2012-03-06 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
PT2043682E (pt) 2006-07-17 2014-07-11 Glaxosmithkline Biolog Sa Vacina da influenza
AU2007276219B2 (en) 2006-07-18 2013-10-03 Glaxosmithkline Biologicals S.A. Vaccines for malaria
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
EP2064230A2 (en) 2006-08-16 2009-06-03 Novartis AG Immunogens from uropathogenic escherichia coli
US9150619B2 (en) * 2006-09-01 2015-10-06 Csl Limited Method of elicting or inducing an immune response
CN103585624A (zh) 2006-09-07 2014-02-19 葛兰素史密丝克莱恩生物有限公司 疫苗
EP3456348B1 (en) 2006-09-11 2025-03-26 Seqirus UK Limited Making influenza virus vaccines without using eggs
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
DK2468300T3 (da) 2006-09-26 2018-01-29 Infectious Disease Res Inst Vaccinesammensætning indeholdende syntetisk adjuvant
EA015817B1 (ru) * 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
CN103550764A (zh) 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
MX351247B (es) 2007-04-04 2017-10-05 Infectious Disease Res Institute Star Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
AU2008248640A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
KR101579947B1 (ko) 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
DK2185191T3 (da) 2007-06-27 2012-12-03 Novartis Ag Influenzavacciner med lavt indhold af tilsætningsstoffer
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR101580660B1 (ko) 2007-08-02 2015-12-28 바이오앤드백스 파마슈티칼즈, 리미티드. 다중체 다중-에피토프 인플루엔자 백신
JP2010535504A (ja) 2007-08-03 2010-11-25 プレジデント アンド フェロウズ オブ ハーバード カレッジ クラミジア抗原
UY31285A1 (es) 2007-08-13 2009-03-31 Vacunas
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
MX2010002965A (es) 2007-09-17 2010-09-14 Oncomethylome Sciences Sa Deteccion mejorada de la expresion de mage-a.
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2008331800A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
EP2227251A1 (en) 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Influenza composition
ES2664753T3 (es) * 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Composiciones de inducción de respuestas inmunes
EP2227483B1 (en) 2007-12-19 2017-04-19 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PT2235046E (pt) 2007-12-21 2012-10-26 Novartis Ag Formas mutantes de estreptolisina o
US8092813B1 (en) 2007-12-28 2012-01-10 Novartis Ag Polychlorinated biphenyls and squalene-containing adjuvants
EP3263591B1 (en) 2008-02-21 2019-03-27 GlaxoSmithKline Biologicals S.A. Meningococcal fhbp polypeptides
US9511131B2 (en) 2008-03-10 2016-12-06 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
CA2720268A1 (en) * 2008-04-09 2009-10-15 Ventria Bioscience Production of ospa for lyme disease control
ES2678694T3 (es) * 2008-04-16 2018-08-16 Glaxosmithkline Biologicals Sa Vacuna
JP2011518186A (ja) 2008-04-18 2011-06-23 ザ ジェネラル ホスピタル コーポレイション 自己集合性ワクチンを使用する免疫療法
CA2826508C (en) 2008-05-23 2016-07-19 The Regents Of The University Of Michigan Nanoemulsion vaccines
CN102112153B (zh) 2008-06-04 2014-04-16 一般财团法人化学及血清疗法研究所 灭活日本脑炎病毒颗粒作为佐剂的用途
WO2009155489A2 (en) 2008-06-19 2009-12-23 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
KR101707569B1 (ko) 2008-08-01 2017-02-16 감마 백신즈 피티와이 리미티드 인플루엔자 백신
WO2010023551A2 (en) * 2008-08-28 2010-03-04 Michael Broeker Production of squalene from hyper-producing yeasts
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010036938A2 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9974844B2 (en) 2008-11-17 2018-05-22 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
GB0822001D0 (en) * 2008-12-02 2009-01-07 Glaxosmithkline Biolog Sa Vaccine
EP2356225A1 (en) 2008-12-03 2011-08-17 Protea Vaccine Technologies Ltd. GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
WO2010077986A2 (en) 2008-12-16 2010-07-08 Baxter International Inc. Production of viral vaccine
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
SG173194A1 (en) * 2009-02-17 2011-09-29 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
EP2408933A2 (en) 2009-03-17 2012-01-25 MDxHealth SA Improved detection of gene expression
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
MX340830B (es) 2009-04-30 2016-07-26 Coley Pharm Group Inc Vacuna neumococica y usos de la misma.
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
JP2012528106A (ja) 2009-05-27 2012-11-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃａｓｂ７４３９構築物
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
CN102802665B (zh) 2009-06-15 2015-11-25 新加坡国立大学 流感疫苗、组合物及使用方法
CN102596243B (zh) 2009-06-16 2015-10-21 密执安大学评议会 纳米乳剂疫苗
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP2451950B9 (en) 2009-07-06 2016-11-23 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
ES2662716T3 (es) 2009-07-07 2018-04-09 Glaxosmithkline Biologicals Sa Inmunógenos conservados de Escherichia coli
AR077757A1 (es) 2009-07-15 2011-09-21 Novartis Ag Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
SG178035A1 (en) 2009-07-16 2012-03-29 Novartis Ag Detoxified escherichia coli immunogens
KR101425405B1 (ko) 2009-07-17 2014-08-01 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
WO2011013034A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
ES2562259T3 (es) 2009-08-27 2016-03-03 Glaxosmithkline Biologicals Sa Polipéptidos híbridos que incluyen secuencias fHBP meningocócicas
CN104548089B (zh) 2009-09-03 2017-09-26 辉瑞疫苗有限责任公司 Pcsk9疫苗
AU2010293902A1 (en) 2009-09-10 2012-03-22 Novartis Ag Combination vaccines against respiratory tract diseases
PL2475384T3 (pl) * 2009-09-10 2017-02-28 Merial, Inc. Nowe formulacje szczepionek obejmujące adiuwanty zawierające saponiny
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
BR112012009014B8 (pt) 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
CA2776874A1 (en) 2009-10-09 2011-04-14 Cbio Limited Chaperonin 10 variants
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
SG10201408505SA (en) 2009-12-22 2015-02-27 Celldex Therapeutics Inc Vaccine compositions
US20110159031A1 (en) 2009-12-22 2011-06-30 Baxter International Inc. Vaccine to Influenza A Virus
EP2519265B1 (en) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013521326A (ja) 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CN102946900A (zh) 2010-03-11 2013-02-27 免疫设计公司 用于大流行流感的疫苗
CN103221065A (zh) 2010-03-26 2013-07-24 葛兰素史密斯克莱生物公司 Hiv疫苗
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
JP2013529894A (ja) 2010-04-07 2013-07-25 ノバルティス アーゲー パルボウイルスｂ１９のウイルス様粒子を生成するための方法
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
EP2575988A1 (en) 2010-05-28 2013-04-10 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
KR101609032B1 (ko) 2010-06-04 2016-04-04 와이어쓰 엘엘씨 스트렙토코커스 뉴모니아 백신 제제
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
AU2011276328C1 (en) 2010-07-06 2016-01-21 Novartis Ag Norovirus derived immunogenic compositions and methods
JP6119030B2 (ja) 2010-07-06 2017-04-26 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザを治療するための組成物及び方法
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US20130259948A1 (en) 2010-09-21 2013-10-03 National Institute Of Immunology Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
EA201390452A1 (ru) 2010-09-27 2013-11-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина
WO2012041669A1 (en) 2010-09-27 2012-04-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
ES2859673T3 (es) 2010-11-08 2021-10-04 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
NZ611176A (en) 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
BR112013017488A2 (pt) 2011-01-06 2017-08-01 Bionor Immuno As peptídeos imunogênicos multiméricos e monoméricos
CA2862871C (en) 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US10342862B2 (en) 2011-01-26 2019-07-09 Glaxosmithkline Biologicals, Sa RSV immunization regimen
AU2012211043B2 (en) 2011-01-27 2017-04-06 Gamma Vaccines Pty Limited Combination vaccines
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
WO2012135177A2 (en) 2011-03-29 2012-10-04 Uab Research Foundation Methods and compositions for cytomegalovirus il-10 protein
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
SG194083A1 (en) 2011-04-08 2013-11-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
LT2707385T (lt) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Iš anksto sulieti rsv f antigenai
SG194733A1 (en) 2011-05-17 2013-12-30 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
US20130156803A1 (en) 2011-06-04 2013-06-20 Rochester General Hospital Research Institute Compositions and methods related to p6
MX2013013627A (es) 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
EP2726097A4 (en) * 2011-07-01 2015-03-11 Univ California HERPES VIRUS VACCINE AND METHOD OF USE
US10030052B2 (en) 2011-07-25 2018-07-24 Glaxosmithkline Biologicals Sa Parvovirus Vp1 unique region polypeptides and compositions thereof
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
EP2747779A4 (en) 2011-08-22 2015-04-08 Nanobio Corp VACCINE AGAINST HERPES SIMPLEX VIRUS IN THE FORM OF NANOEMULSION
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
US9561271B2 (en) 2011-09-09 2017-02-07 Nanobio Corporation Nanoemulsion respiratory syncytial virus (RSV) subunit vaccine
JP2014531442A (ja) 2011-09-14 2014-11-27 ノバルティス アーゲー Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉワクチンの組み合わせ
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
PE20141547A1 (es) 2011-09-16 2014-10-25 Ucb Pharma Sa Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
LT2782598T (lt) 2011-11-23 2020-07-27 In3Bio Ltd. Rekombinantiniai baltymai ir jų terapinis panaudojimas
EP2788477A2 (en) 2011-12-07 2014-10-15 Institut Pasteur Identification of a swine parecho-like virus and applications
CN103974718A (zh) 2011-12-08 2014-08-06 诺华股份有限公司 基于艰难梭菌毒素的疫苗
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTICS
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
JP2015509713A (ja) 2012-02-24 2015-04-02 ノバルティス アーゲー 線毛タンパク質および組成物
WO2013134577A2 (en) 2012-03-08 2013-09-12 Detectogen, Inc. Leishmaniasis antigen detection assays and vaccines
NZ630807A (en) 2012-03-23 2016-04-29 Pitney Pharmaceuticals Pty Ltd Kinase inhibitors for the treatment of cancer
GB201205189D0 (en) 2012-03-23 2012-05-09 Glaxosmithkline Biolog Sa Novel medical use
WO2013150518A1 (en) 2012-04-01 2013-10-10 Rappaport Family Institute For Research In The Medical Sciences Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
US9821050B2 (en) 2012-04-02 2017-11-21 The University Of North Carolina At Chapel Hill Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
CA2871520C (en) 2012-04-26 2020-12-29 Novartis Ag Antigens from non-typeable h. influenzae
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
PE20142406A1 (es) 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
JP6619648B2 (ja) 2012-05-16 2019-12-11 イミューン デザイン コーポレイション Ｈｓｖ−２のためのワクチン
KR20150021933A (ko) 2012-05-22 2015-03-03 노파르티스 아게 수막염구균 혈청군 x 포합체
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
CN104717971A (zh) 2012-06-05 2015-06-17 澳大利亚国立大学 用白介素-4拮抗剂进行疫苗接种
AU2013273482A1 (en) 2012-06-06 2014-12-11 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
CN104812408A (zh) 2012-07-24 2015-07-29 赛诺菲巴斯德有限公司 用于防止登革热病毒感染的疫苗组合物
SG10201912291YA (en) 2012-07-24 2020-02-27 Sanofi Pasteur Vaccine compositions
NZ704005A (en) 2012-08-01 2016-07-29 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
HUE065746T2 (hu) 2012-08-03 2024-06-28 Access To Advanced Health Inst Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére
ES2627099T3 (es) 2012-08-06 2017-07-26 Pitney Pharmaceuticals Pty Limited Compuestos para el tratamiento de enfermedades relacionadas con la vía de mTOR
JP2014040396A (ja) * 2012-08-23 2014-03-06 Chemo-Sero-Therapeutic Research Institute 脂質異常症治療薬を含有するアジュバント組成物
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
US10232035B2 (en) 2012-09-14 2019-03-19 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes virus and use thereof in vaccines
JP6283674B2 (ja) 2012-09-18 2018-02-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 外膜小胞
ES2672996T3 (es) 2012-10-02 2018-06-19 Glaxosmithkline Biologicals Sa Conjugados de sacáridos no lineales
AR092897A1 (es) 2012-10-03 2015-05-06 Novartis Ag Composiciones inmunogenicas
EP3859004A1 (en) 2012-10-24 2021-08-04 Platelet Targeted Therapeutics LLC Platelet targeted treatment
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
RS56886B1 (sr) 2012-11-30 2018-04-30 Glaxosmithkline Biologicals Sa Antigeni pseudomonasa i kombinacije antigena
TR201905272T4 (tr) 2012-12-05 2019-05-21 Glaxosmithkline Biologicals Sa İmmünojenik bileşim.
TR201907858T4 (tr) 2012-12-17 2019-06-21 Newsouth Innovations Pty Ltd Müsinin rol oynadığı hastalıkların tedavisi.
US10357538B2 (en) 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
JP6494527B2 (ja) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
KR102427429B1 (ko) 2013-03-15 2022-08-01 인3바이오 리미티드 자기조립형 합성 단백질
EP2978447B1 (en) 2013-03-28 2019-05-08 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
WO2014182872A1 (en) 2013-05-08 2014-11-13 Protatek International, Inc. Vaccine for pcv2 and mycoplasma
EP3689375A1 (en) 2013-05-15 2020-08-05 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
ES2745431T3 (es) 2013-06-26 2020-03-02 Univ North Carolina Chapel Hill Composiciones para vacunas contra el virus del dengue y su uso
WO2015000014A1 (en) 2013-07-01 2015-01-08 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
US9975925B2 (en) 2013-08-28 2018-05-22 Glaxosmithkline Biologicals S.A. Influenza antigens and antibodies
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
WO2015063611A2 (en) 2013-11-01 2015-05-07 University Of Oslo Albumin variants and uses thereof
US9993541B2 (en) 2013-11-13 2018-06-12 University Of Oslo Outer membrane vesicles and uses thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
CA2931112A1 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Pan pollen immunogens and methods and uses for immune response modulation
WO2015077442A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses for immune response modulation
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
MX2016008640A (es) 2013-12-31 2016-10-07 Infectious Disease Res Inst Formulaciones de vacuna de vial unico.
WO2015103104A1 (en) 2014-01-06 2015-07-09 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated salmonella enterica
MX2016009464A (es) 2014-01-21 2017-01-16 Immune Design Corp Composiciones para el uso en el tratamiento de afecciones alergicas.
DK3096785T3 (da) 2014-01-21 2020-09-21 Pfizer Immunogene sammensætninger omfattende konjugerede kapsel-saccharid-antigener og anvendelser deraf
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
WO2015151103A1 (en) 2014-04-03 2015-10-08 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
PH12016502345B1 (en) 2014-05-28 2023-03-01 Agenus Inc Anti-gitr antibodies and methods of use thereof
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
CN106715458A (zh) 2014-07-18 2017-05-24 华盛顿大学 癌症疫苗组合物及其使用方法
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
BR112017001417B1 (pt) 2014-07-23 2023-11-07 Children's Hospital & Research Center At Oakland Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada
US11083788B2 (en) 2014-10-10 2021-08-10 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
BR112017008952A2 (pt) 2014-11-02 2018-01-16 Univ North Carolina Chapel Hill métodos e composições para vírus recombinantes da dengue para desenvolvimento de vacina e diagnóstico
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
US20170281744A1 (en) 2014-12-10 2017-10-05 Glaxosmithkline Biologicals Sa Method of treatment
CA2972635A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
SI3244917T1 (sl) 2015-01-15 2023-07-31 Pfizer Inc. Imunogenske kompozicije za uporabo v pnevmokoknih cepivih
WO2016134300A1 (en) 2015-02-20 2016-08-25 Board Of Regents, The University Of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
WO2016141320A2 (en) 2015-03-05 2016-09-09 Northwestern University Non-neuroinvasive viruses and uses thereof
EP3270897A4 (en) 2015-03-20 2018-12-05 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
EP3273989B1 (en) 2015-03-26 2023-12-27 Gpn Vaccines Pty Ltd Streptococcal vaccine
US10682314B2 (en) 2015-05-26 2020-06-16 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
US10576131B2 (en) 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
EP3319988A1 (en) 2015-07-07 2018-05-16 Affiris AG Vaccines for the treatment and prevention of ige mediated diseases
EP3325008A1 (en) 2015-07-21 2018-05-30 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3341017B1 (en) 2015-08-25 2024-10-16 Babita Agrawal Immunomodulatory compositions comprising caulobacter crescentus and use thereof
MA48579A (fr) 2015-09-01 2020-03-18 Agenus Inc Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
ES2607715B1 (es) 2015-10-01 2018-01-17 Solutex Na, Lcc Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
JP7098519B2 (ja) 2015-10-08 2022-07-11 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ Ｃ型肝炎ウイルスｅ１／ｅ２ヘテロダイマー及びそれを生成する方法
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
SI3405212T1 (sl) 2016-01-19 2020-09-30 Pfizer Inc. Cepiva proti raku
GB201603625D0 (en) 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
WO2017156461A2 (en) 2016-03-10 2017-09-14 Aperisys, Inc. Antigen-binding fusion proteins with modified hsp70 domains
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
EP3430039A1 (en) 2016-03-14 2019-01-23 Universitetet I Oslo Engineered immunoglobulins with altered fcrn binding
WO2017167768A1 (en) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Novel vaccine composition
ES2929054T3 (es) 2016-05-16 2022-11-24 Access To Advanced Health Inst Formulación que contiene un agonista de TLR y métodos de uso
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
MX2018014270A (es) 2016-05-21 2019-02-14 Infectious Disease Res Inst Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
SG10201912563XA (en) 2016-05-27 2020-02-27 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
IL315825A (en) 2016-06-01 2024-11-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
CN109863169A (zh) 2016-08-23 2019-06-07 葛兰素史密丝克莱恩生物有限公司 具有连接至不变链(cd74)的短片段的抗原的融合肽
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
BR112019004913B1 (pt) 2016-09-16 2022-07-12 Infectious Disease Research Institute Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
TWI773694B (zh) 2016-10-11 2022-08-11 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CN110198954A (zh) 2017-01-13 2019-09-03 艾吉纳斯公司 与ny-eso-1结合的t细胞受体和其使用方法
HUE059252T2 (hu) 2017-01-20 2022-11-28 Pfizer Immunogén készítmények pneumokokkusz vakcinákban történõ alkalmazásra
JP7291398B2 (ja) 2017-03-30 2023-06-15 ザ ユニバーシティー オブ クイーンズランド キメラ分子およびその使用
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
TWI842672B (zh) 2017-04-13 2024-05-21 美商艾吉納斯公司 抗ｃｄ１３７抗體及其使用方法
TWI805582B (zh) 2017-05-01 2023-06-21 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
US20200115324A1 (en) 2017-06-11 2020-04-16 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
BR112019026615B1 (pt) 2017-06-15 2022-08-02 Infectious Disease Research Institute Carreadores lipídicos nanoestruturados e emulsões estáveis e usos dos mesmos
IL300235A (en) 2017-07-18 2023-03-01 In3Bio Ltd Synthetic proteins and their therapeutic uses
CN110996994A (zh) 2017-08-14 2020-04-10 葛兰素史密丝克莱恩生物有限公司 加强免疫应答的方法
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
AU2018326875A1 (en) 2017-09-04 2020-03-19 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
EP3678698A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
KR102755593B1 (ko) 2017-09-08 2025-01-20 액세스 투 어드밴스드 헬스 인스티튜트 사포닌을 포함하는 리포솜 제형 및 사용 방법
US11566050B2 (en) 2017-10-18 2023-01-31 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus vaccines and diagnostics
WO2019090238A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
JP2021526831A (ja) 2018-06-12 2021-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
EP3840770A1 (en) 2018-08-23 2021-06-30 GlaxoSmithKline Biologicals SA Immunogenic proteins and compositions
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20210340185A1 (en) 2018-08-29 2021-11-04 Centre Hospitalier Universitaire Vaudois Ebola vaccine compositions and methods of using same
EP3851120A4 (en) 2018-09-11 2022-04-27 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
EP3890775A1 (en) 2018-12-06 2021-10-13 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
JP7551618B2 (ja) 2018-12-12 2024-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US20220184158A1 (en) 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
EP3934687A1 (en) 2019-03-05 2022-01-12 GlaxoSmithKline Biologicals S.A. Hepatitis b immunisation regimen and compositions
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2020212461A1 (en) 2019-04-18 2020-10-22 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
AU2020283768A1 (en) 2019-05-25 2021-12-23 Access To Advanced Health Institute Composition and method for spray drying an adjuvant vaccine emulsion
BR112021026132A2 (pt) 2019-06-25 2022-02-08 In3Bio Ltd Proteínas sintéticas quiméricas estabilizadas e usos terapêuticos das mesmas
WO2021013798A1 (en) 2019-07-21 2021-01-28 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
WO2021023691A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Immunogenic composition
EP4477230A2 (en) 2019-08-06 2024-12-18 The University of North Carolina at Chapel Hill Methods and compositions for stabilized recombinant flavivirus e protein dimers
JP2022545741A (ja) 2019-08-30 2022-10-28 アジェナス インコーポレイテッド 抗ｃｄ９６抗体およびその使用方法
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
EP3808765A1 (en) 2019-10-14 2021-04-21 ETH Zurich Cell line for tcr discovery and engineering and methods of use thereof
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
NL2027383B1 (en) 2020-01-24 2022-04-06 Aim Immunotech Inc Methods, compositions, and vaccines for treating a virus infection
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
BR112022015796A2 (pt) 2020-02-21 2022-10-11 Pfizer Purificação de sacarídeos
WO2021165928A2 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2023514825A (ja) 2020-02-26 2023-04-11 ヴェルシテック リミテッド コロナウイルス感染症に対するｐｄ－１ベースのワクチン
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
EP4132478A1 (en) 2020-04-09 2023-02-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
WO2022002783A1 (en) 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa Adjuvants
AU2021327129A1 (en) 2020-08-17 2023-03-30 Universität Basel Lfa-1 signalling mediator for use in cancer therapy
TW202228770A (zh) 2020-08-24 2022-08-01 美商賽諾菲巴斯德公司 具有含有生育酚之鯊烯乳劑佐劑之covid-19疫苗
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
WO2022083760A1 (zh) 2020-10-23 2022-04-28 江苏省疾病预防控制中心(江苏省公共卫生研究院) 融合蛋白及其应用
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2023546615A (ja) 2020-10-27 2023-11-06 ファイザー・インク 大腸菌組成物およびその方法
MX2023005221A (es) 2020-11-04 2023-05-16 Pfizer Composiciones inmunogenicas para uso en vacunas neumococicas.
JP2023549736A (ja) 2020-11-10 2023-11-29 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
CA3211240A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
US20240165224A1 (en) 2021-03-26 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2022281543A1 (en) 2021-05-28 2023-11-23 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2024528504A (ja) 2021-06-28 2024-07-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規インフルエンザ抗原
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides
EP4433080A1 (en) 2021-11-18 2024-09-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
CN118510548A (zh) 2022-01-13 2024-08-16 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CN114984201A (zh) * 2022-04-24 2022-09-02 国药中生生物技术研究院有限公司 类天然脂滴纳米乳佐剂及其制备方法
KR20250008122A (ko) 2022-05-11 2025-01-14 화이자 인코포레이티드 보존제를 갖는 백신 제형의 제조 방법
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024180262A1 (en) 2023-03-02 2024-09-06 Sanofi Compositions for use in treatment of chlamydia
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20240374698A1 (en) 2023-05-05 2024-11-14 Sanofi Compositions for use in treatment of acne
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
JP2746272B2 (ja) * 1987-11-03 1998-05-06 シンテツクス（ユー エス エイ）インコーポレーテツド ワクチンアジュバント
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2068989T3 (es) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
NZ238731A (en) * 1990-06-27 1996-02-27 Univ Emory Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
AU654824B2 (en) * 1990-06-29 1994-11-24 Chiron Corporation Vaccine compositions containing liposomes
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
WO1992006113A2 (en) * 1990-09-28 1992-04-16 Smithkline Beecham Biologicals (S.A.) DERIVATIVES OF gp160 AND VACCINES BASED ON gp160 OR A DERIVATIVE THEREOF, CONTAINING AN ADJUVANT
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DE69225710T3 (de) * 1991-07-25 2004-10-14 Idec Pharmaceuticals Corp., San Diego Anregung von antworten zytotoxischer t-lymphozyten
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0761231B1 (en) * 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
DK0812593T4 (da) * 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
RU2160119C2 (ru) * 1993-05-25 2000-12-10 Американ Цианамид Компани Вакцинная композиция, содержащая белок респираторно-синцитиального вируса (варианты)
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
US6146632A (en) 2000-11-14
HK1012243A1 (en) 1999-07-30
SI0735898T1 (en) 1999-06-30
CA2179779A1 (en) 1995-06-29
DE69417063T2 (de) 1999-10-28
EP1327451B1 (en) 2007-04-18
US7029678B2 (en) 2006-04-18
CN1138298A (zh) 1996-12-18
ZA9410176B (en) 1995-11-17
NZ277802A (en) 1998-04-27
CY2593B2 (en) 2009-11-04
ES2285036T3 (es) 2007-11-16
GR3029750T3 (en) 1999-06-30
HK1057991A1 (en) 2004-04-30
DE122008000054I1 (de) 2009-02-19
DK0735898T3 (da) 1999-08-23
PT868918E (pt) 2004-08-31
EP0868918A3 (en) 2000-04-26
JPH09506887A (ja) 1997-07-08
EP0868918A2 (en) 1998-10-07
US20040043038A1 (en) 2004-03-04
DE122008000055I1 (de) 2009-02-19
LU91486I2 (fr) 2008-12-15
EP1792628A1 (en) 2007-06-06
EP1327451A1 (en) 2003-07-16
NZ329661A (en) 2005-03-24
US7169391B2 (en) 2007-01-30
DK0868918T3 (da) 2004-08-16
NL300363I1 (nl) 2009-01-05
ES2129801T3 (es) 1999-06-16
US6623739B1 (en) 2003-09-23
NL300362I1 (nl) 2009-01-05
AU705521B2 (en) 1999-05-27
CA2179779C (en) 2010-04-20
DE69434956D1 (de) 2007-05-31
JP2006249080A (ja) 2006-09-21
JP4125781B2 (ja) 2008-07-30
DE69433750T2 (de) 2005-08-04
DE69417063D1 (de) 1999-04-15
AU6803198A (en) 1998-07-09
LU91485I2 (fr) 2008-12-15
DE69433750D1 (de) 2004-06-03
PT1327451E (pt) 2007-07-23
AU687494B2 (en) 1998-02-26
EP0735898B1 (en) 1999-03-10
AU705519B2 (en) 1999-05-27
AU1316695A (en) 1995-07-10
SI1327451T1 (sl) 2007-08-31
GB9326253D0 (en) 1994-02-23
SG49257A1 (en) 1998-05-18
ATE265228T1 (de) 2004-05-15
HK1021504A1 (en) 2000-06-16
ES2219837T3 (es) 2004-12-01
SI0868918T1 (en) 2004-08-31
SG73578A1 (en) 2000-06-20
KR100350965B1 (ko) 2003-02-25
EP0735898A1 (en) 1996-10-09
WO1995017209A1 (en) 1995-06-29
JP4126067B2 (ja) 2008-07-30
JP2007231029A (ja) 2007-09-13
EP0868918B1 (en) 2004-04-28
US20070134268A1 (en) 2007-06-14
WO1995017210A1 (en) 1995-06-29
JP4126079B2 (ja) 2008-07-30
DE69434956T2 (de) 2008-01-17
US7510698B2 (en) 2009-03-31
US20060182753A1 (en) 2006-08-17
AU6803298A (en) 1998-07-09
AU1316495A (en) 1995-07-10
CY2530B1 (en) 2006-04-12
DK1327451T3 (da) 2007-08-20
ATE177322T1 (de) 1999-03-15
ATE359818T1 (de) 2007-05-15

Similar Documents

Publication Publication Date Title
CN1086589C (zh) 疫苗
CN1122530C (zh) 疫苗
CN1289065C (zh) 含有皂苷和固醇的疫苗
CN1091978A (zh) 粒细胞-巨噬细胞-集落刺激因子作为疫苗佐剂的用途
CN1434864A (zh) 增强对单纯疱疹病毒疫苗的免疫应答的方法
Lu et al. Enhanced protective immune response of foot-and-mouth disease vaccine through DNA-loaded virus-like particles
NZ250555A (en) Vaccine with enhanced immunogenicity by inclusion of a cytokine
CN1295480A (zh) 含有白细胞介素－12和呼吸道合胞病毒抗原的疫苗
AU687494C (en) Vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20020626

Termination date: 20101220